TSXV: VIMYInvestor Centre
Vimy Pharma
Contact us

Canadian roots. Global impact.

A healthier tomorrow, built here.

Vimy Pharma is building a reliable supply of high-quality, affordable essential medicines, starting with generic semaglutide.

What we do

Pending Health Canada approval

Advancing essential medicines for a healthier tomorrow.

Semaglutide is on the World Health Organization’s list of essential medicines.1 Vimy-semaglutide and Vimy-semaglutide (WT) are generic medicines, developed and manufactured in Canada to Health Canada’s rigorous standards.

Two submissions

Generic Ozempic® (May 2026) and generic Wegovy® (August 2026), filed with Health Canada.

10+ million units a year

Planned initial capacity, enough for 750,000 Canadian patients, with the potential to expand capacity 4 times.2

One third of the brand price

Planned pricing, opening access for millions more Canadians.3

Supplied in vials

Space-efficient cold chain storage, robust supply.

About Vimy-semaglutide

MY Health: Reliable. Affordable.Canadian.

Prioritize your long-term health with high-quality, Canadian-manufactured medicines that are in reliable supply, accessible and affordable.

Vimy Pharma’s injectable semaglutide products are pending Health Canada approval.

Why it matters

Managing our long-term health has never been more important.

5 million

Canadians living with type 2 diabetes4

10 million

Canadians living with obesity5

1 million+

Canadians currently treated with injectable semaglutide6

Stronger supply chains.Certain tomorrows.

Building a more resilient healthcare system for Canada and beyond.

Reliable supply

Built to produce an abundant supply of a medicine that has faced shortages.7

Pharmaceutical sovereignty

Canada currently depends on foreign-made injectable semaglutide.

Canada can be the pharmacy to the world

Partnerships to supply Vimy-semaglutide and Vimy-semaglutide (WT) to markets in Middle East, Africa and LATAM, where generic semaglutide is able to be sold.

Canadian, coast to coast.

Built across Canada, with plans to expand capacity to serve the Canadian market and available export markets.2

Manufactured in Canada

Who will get us there

Led by people who’ve done this before.

Meet the team
Farris Smith, President, and Dave Suchon, CEO, of Vimy Pharma
Members of management, Farris Smith, President, and Dave Suchon, CEO, former Novo Nordisk Canadian leadership.

Latest news

All news
Sources and notes
  1. World Health Organization, WHO Model List of Essential Medicines, 24th List, September 5, 2025.
  2. Company estimate. Assumes about 13 units per patient per year. Capacity and expansion plans are forward-looking and subject to regulatory approval, financing and operational factors.
  3. Company estimate, compared with an average of about $227 per Ozempic® pen derived from public list price with ODB. Final pricing will be set at launch.
  4. Diabetes Canada, Diabetes in Canada: Backgrounder, October 2024. About 5.8 million people living with diabetes in 2024; type 1 represents 5–10%, implying roughly 5.2–5.5 million with type 2.
  5. Obesity Canada’s reported obesity prevalence of 26.4% (BMI ≥ 30) applied to Statistics Canada’s population estimate of 41,798,407 (July 1, 2026), about 11.0 million, rounded down.
  6. IQVIA Canada, semaglutide (Ozempic® and Wegovy®) unit sales, MAT; equivalent to more than 1 million patients treated for a full year at about one pen per month.
  7. Health Canada, Drug Shortages in Canada: Fiscal Year 2023 to 2024 in Review, November 2024; Health Canada drug shortage database (healthproductshortages.ca), accessed October 28, 2026.